Zydus Lifesci.

Market Cap: Mid Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE010B01027
NSEID: ZYDUSLIFE
BSEID: 532321
View on NSE | View on BSE

INR

910.05

3.3 (0.36%)

BSENSE

Feb 18

BSE+NSE Vol: 3.1 lacs

{
  "main_header": {
    "sid": 290229,
    "name": "Zydus Lifesci.",
    "stock_name": "Zydus Lifesci.",
    "full_name": "Zydus Lifesciences Ltd",
    "name_url": "stocks-analysis/zydus-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "910.05",
    "chg": 3.3,
    "chgp": "0.36%",
    "dir": 1,
    "prev_price": "906.75",
    "mcapval": "91,275.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532321,
    "symbol": "ZYDUSLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE010B01027",
    "curr_date": "Feb 18",
    "curr_time": "",
    "bse_nse_vol": "3.1 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 18, 2026",
    "traded_date_str": "2026 02 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zydus-lifesci-290229-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Zydus Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-3843257",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_technicaldot_3843257.png",
        "date": "2026-02-17 08:01:40",
        "description": "Zydus Lifesciences Ltd has experienced a subtle yet significant shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 0.57%, the stock’s technical indicators reveal a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical parameter changes and what they imply for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesciences-ltd-is-rated-sell-by-marketsmojo-3842402",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_mojoScore_3842402.png",
        "date": "2026-02-16 10:10:04",
        "description": "Zydus Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Zydus Lifesciences Ltd Faces Bearish Momentum Amid Technical Indicator Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-ltd-faces-bearish-momentum-amid-technical-indicator-shifts-3841399",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_technicaldot_3841399.png",
        "date": "2026-02-16 08:01:04",
        "description": "Zydus Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s price action and technical parameters reveal a complex interplay of bearish and mildly bullish signals, warranting a detailed analysis for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Zydus Lifesciences Gains 1.91%: 5 Key Factors Driving This Week’s Mixed Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-gains-191-5-key-factors-driving-this-weeks-mixed-momentum-3840721",
        "imagepath": "",
        "date": "2026-02-15 10:00:12",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>9 Feb:</strong> Sharp surge in open interest with bullish derivatives activity and a 3.97% price gain to Rs.923.10</p>\n                    <p><strong>10 Feb:</strong> Open interest rose again amid bearish signals; stock declined 3.89% to Rs.887.20</p>\n                    <p><strong>11 Feb:</strong> Mild recovery with 1.22% gain to Rs.898.05 amid mixed technical momentum</p>\n                    <p><strong>12 Feb:</strong> Price rose 2.53% to Rs.920.80 despite Sensex decline</p>\n                    <p><strong>13 Feb:</strong> Week ended with a 1.73% drop to Rs.904.85 amid mixed market signals</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <di..."
      },
      {
        "title": "Zydus Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-3836464",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_technicaldot_3836464.png",
        "date": "2026-02-13 08:01:17",
        "description": "Zydus Lifesciences Ltd has experienced a subtle but notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook as of early 2026. Despite a positive day change of 2.22% to close at ₹918.00, the stock’s technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes. This analysis delves into the recent technical parameter changes, evaluating key momentum indicators such as MACD, RSI, moving averages, and volume trends to provide a comprehensive view of the stock’s near-term trajectory."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-bearish-market-signals-3831262",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3831262.png",
        "date": "2026-02-10 15:00:09",
        "description": "Zydus Lifesciences Ltd has witnessed a significant 33.1% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock underperformed its sector and broader indices, raising questions about the directional bets underpinning this surge."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-bearish-market-signals-3831214",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3831214.png",
        "date": "2026-02-10 14:00:09",
        "description": "Zydus Lifesciences Ltd has witnessed a significant surge in open interest in its derivatives segment, coinciding with a notable decline in its share price and underperformance relative to its sector and benchmark indices. This sudden increase in open interest, coupled with elevated volumes and bearish price action, signals a shift in market positioning and potential directional bets among traders and investors."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-bearish-market-signals-3831176",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3831176.png",
        "date": "2026-02-10 13:00:12",
        "description": "Zydus Lifesciences Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite the uptick in volumes, the stock underperformed its sector and broader indices, raising questions about the directional bets being placed by traders amid a cautious outlook for the pharmaceutical giant."
      },
      {
        "title": "Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-sees-sharp-open-interest-surge-amid-bearish-market-signals-3831150",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ZydusLifescienc_oi_spurts_by_underlying_3831150.png",
        "date": "2026-02-10 12:00:10",
        "description": "Zydus Lifesciences Ltd (ZYDUSLIFE) has witnessed a significant surge in open interest in its derivatives segment, with a 29.6% increase to 30,845 contracts from 23,796 previously. This spike accompanies a notable decline in the stock price, underperforming its sector and broader market indices, signalling a shift in market positioning and investor sentiment towards a more cautious or bearish stance."
      }
    ],
    "total": 606,
    "sid": "290229",
    "stock_news_url": "https://www.marketsmojo.com/news/zydus-lifesciences-290229"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "15-Feb-2026",
      "details": "Transcript of the post results earnings call held on February 10 2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "14-Feb-2026",
      "details": "Zydus receives final approval from USFDA for Ammonium Lactate Cream 12%.",
      "source": "BSE"
    },
    {
      "caption": "Update On Litigation",
      "datetime": "12-Feb-2026",
      "details": "Update on litigation",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has declared <strong>1100%</strong> dividend, ex-date: 25 Jul 25",
          "dt": "2025-07-25",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:5</strong> stock split, ex-date: 06 Oct 15",
          "dt": "2015-10-06",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 05 Apr 10",
          "dt": "2010-04-05",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Zydus Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-17 08:01:40

Zydus Lifesciences Ltd has experienced a subtle yet significant shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 0.57%, the stock’s technical indicators reveal a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical parameter changes and what they imply for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Zydus Lifesciences Ltd is Rated Sell by MarketsMOJO

2026-02-16 10:10:04

Zydus Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Zydus Lifesciences Ltd Faces Bearish Momentum Amid Technical Indicator Shifts

2026-02-16 08:01:04

Zydus Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s price action and technical parameters reveal a complex interplay of bearish and mildly bullish signals, warranting a detailed analysis for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Zydus Lifesciences Gains 1.91%: 5 Key Factors Driving This Week’s Mixed Momentum

2026-02-15 10:00:12

Key Events This Week

9 Feb: Sharp surge in open interest with bullish derivatives activity and a 3.97% price gain to Rs.923.10

10 Feb: Open interest rose again amid bearish signals; stock declined 3.89% to Rs.887.20

11 Feb: Mild recovery with 1.22% gain to Rs.898.05 amid mixed technical momentum

12 Feb: Price rose 2.53% to Rs.920.80 despite Sensex decline

13 Feb: Week ended with a 1.73% drop to Rs.904.85 amid mixed market signals

Read full news article

Zydus Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-13 08:01:17

Zydus Lifesciences Ltd has experienced a subtle but notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook as of early 2026. Despite a positive day change of 2.22% to close at ₹918.00, the stock’s technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes. This analysis delves into the recent technical parameter changes, evaluating key momentum indicators such as MACD, RSI, moving averages, and volume trends to provide a comprehensive view of the stock’s near-term trajectory.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals

2026-02-10 15:00:09

Zydus Lifesciences Ltd has witnessed a significant 33.1% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock underperformed its sector and broader indices, raising questions about the directional bets underpinning this surge.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals

2026-02-10 14:00:09

Zydus Lifesciences Ltd has witnessed a significant surge in open interest in its derivatives segment, coinciding with a notable decline in its share price and underperformance relative to its sector and benchmark indices. This sudden increase in open interest, coupled with elevated volumes and bearish price action, signals a shift in market positioning and potential directional bets among traders and investors.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals

2026-02-10 13:00:12

Zydus Lifesciences Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite the uptick in volumes, the stock underperformed its sector and broader indices, raising questions about the directional bets being placed by traders amid a cautious outlook for the pharmaceutical giant.

Read full news article

Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bearish Market Signals

2026-02-10 12:00:10

Zydus Lifesciences Ltd (ZYDUSLIFE) has witnessed a significant surge in open interest in its derivatives segment, with a 29.6% increase to 30,845 contracts from 23,796 previously. This spike accompanies a notable decline in the stock price, underperforming its sector and broader market indices, signalling a shift in market positioning and investor sentiment towards a more cautious or bearish stance.